Radiation exposure, the ATM gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study

Journal of the National Cancer Institute

Volumn 102, Issue 7, 2010, Pages 475-483

  Bernstein, Jonine L ^a   Haile, Robert W ^b   Stovall, Marilyn ^c   Boice Jr , John D ^d,e   Shore, Roy E ^f,g   Langholz, Bryan ^b   Thomas, Duncan C ^b   Bernstein, Leslie ^h   Lynch, Charles F ⁱ   Olsen, Jorgen H ^j   Malone, Kathleen E ^k   Mellemkjaer, Lene ^j   Borresen Dale, Anne Lise ^l,m   Rosenstein, Barry S ⁿ   Teraoka, Sharon N ^o   Diep, Anh T ^b   Smith, Susan A ^c   Capanu, Marinela ^a   Reiner, Anne S ^a   Liang, Xiaolin ^a   Gatti, Richard A ^p   Concannon, Patrick ^o   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

^f NEW YORK UNIVERSITY   (United States)

^g RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^k USA   (United States)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

^m UNIVERSITY OF OSLO   (Norway)

ⁿ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF VIRGINIA   (United States)

^p UCLA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ATM GENE; BREAST CANCER; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; ETHNICITY; FEMALE; GENE; GENE MUTATION; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; IONIZING RADIATION; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PRIORITY JOURNAL; RACE; RADIATION EXPOSURE; AGE; AGED; BREAST TUMOR; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; DNA DAMAGE; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION; GENETICS; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY; RADIATION INDUCED NEOPLASM; RADIATION INJURY; RISK; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; TIME;

ATM PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; DNA DAMAGE; DNA-BINDING PROTEINS; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERNATIONAL COOPERATION; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; PROTEIN-SERINE-THREONINE KINASES; RADIATION INJURIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 77950574815     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq055     Document Type: Article

References (57)

1. Bernstein JL, Thompson WD, Risch N, Holford TR. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol. 1992;136(8):925-936.
2. Bernstein JL, Thompson WD, Risch N, Holford TR. The genetic epidemiology of second primary breast cancer. Am J Epidemiol. 1992;136(8):937-948.
3. Hoover RN. New malignancies following breast cancer. New Malignancies Among Cancer Survivors: SEER CANCER REGISTRIES, 1973-2000. In: Curtis RE, Freedman DM, Ron E, et al, eds. National Cancer Institute, NIH Publ No. 05-5302. Bethesda, M. 2006:181-205.
4. Hemminki K, Ji J, Forsti A. Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res. 2007;67(3):868-870. (Pubitemid 46270738)
5. Hemminki K, Zhang H, Sundquist J, Lorenzo Bermejo J. Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer. Breast Cancer Res Treat. 2008;111(1):165-169. (Pubitemid 352009228)
6. Innos K, Horn-Ross PL. Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2008;111(3):531-540.
7. Largent JA, Capanu M, Bernstein L, et al. Reproductive history and risk of second primary breast cancer: the WECARE study. Cancer Epidemiol Biomarkers Prev. 2007;16(5):906-911. (Pubitemid 46910090)
8. Shih HA, Nathanson KL, Seal S, et al. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res. 2000;6(11):4259-4264.
9. Stovall M, Smith SA, Langholz BM, et al. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys. 2008;72(4):1021-1030. (Pubitemid 351272614)
10. Yadav BS, Sharma SC, Patel FD, Ghoshal S, Kapoor RK. Second primary in the contralateral breast after treatment of breast cancer. Radiother Oncol. 2008;86(2):171-176. (Pubitemid 351215194)
11. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98(8):1457-1466. (Pubitemid 351543573)
12. Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA. 2008;299(2):194-201.
13. Fletcher O, Johnson N, Dos Santos Silva I, et al. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomarkers Prev. 2009;18(1):230-234.
14. Malone KE, Begg CB, Haile RW, et al. A population-based study of the relative and absolute risks of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J. Clin. Oncol. 2009.
15. Mellemkjaer L, Dahl C, Olsen JH, et al. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study. Br J Cancer. 2008;98(4):728-733. (Pubitemid 351272614)
16. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328-2335. (Pubitemid 41115389)
17. Rogozinska-Szczepka J, Utracka-Hutka B, Grzybowska E, et al. BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. Ann Oncol. 2004;15(9):1373-1376. (Pubitemid 39295026)
18. Bertelsen L, Bernstein L, Olsen JH, et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2008;100(1):32-40. (Pubitemid 351767339)
19. Hooning MJ, Aleman BM, Hauptmann M, et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol. 2008;26(34):5561-5568.
20. Boice JD Jr., Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992;326(12):781-785.
21. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56(4):1038-1045. (Pubitemid 36794035)
22. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268(5218):1749-1753.
23. Savitsky K, Sfez S, Tagle DA, et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet. 1995;4(11):2025-2032.
24. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst. 1986;77(1):89-92. (Pubitemid 16077187)
25. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421(6922):499-506.
26. Taylor AM, Harnden DG, Arlett CF, et al. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature. 1975;258(5534):427-429.
27. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science. 1999;286(5442):1162-1166. (Pubitemid 129515811)
28. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316(5828):1160-1166. (Pubitemid 46877472)
29. Cavaciuti E, Lauge A, Janin N, et al. Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. Genes Chromosomes Cancer. 2005;42(1):1-9. (Pubitemid 39578660)
30. Janin N, Andrieu N, Ossian K, et al. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer. 1999;80(7):1042-1045. (Pubitemid 29233926)
31. Olsen JH, Hahnemann JM, Borresen-Dale AL, et al. Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. Br J Cancer. 2005;93(2):260-265.
32. Pippard EC, Hall AJ, Barker DJ, Bridges BA. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res. 1988;48(10):2929-2932.
33. Stankovic T, Kidd AM, Sutcliffe A, et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet. 1998;62(2):334-345. (Pubitemid 28110776)
34. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991;325(26):1831- 1836.
35. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987;316(21):1289-1294. (Pubitemid 17084026)
36. Swift M, Sholman L, Perry M, Chase C. Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res. 1976;36(1):209-215.
37. Baynes C, Healey CS, Pooley KA, et al. Common variants in the ATM, "RCA1, "RCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res. 2007;9(2):R27. (Pubitemid 350215160)
38. Bernstein JL, Teraoka S, Southey MC, et al. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum Mutat. 2006;27(11):1122-1128. (Pubitemid 44730507)
39. Broeks A, Urbanus JH, Floore AN, et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet. 2000;66(2):494-500. (Pubitemid 30468827)
40. Chenevix-Trench G, Spurdle AB, Gatei M, et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 2002;94(3):205-215. (Pubitemid 34162754)
41. FitzGerald MG, Bean JM, Hegde SR, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997;15(3):307-310.
42. Szabo CI, Schutte M, Broeks A, et al. Are ATM mutations 7271T->G and IVS10-6T->G really high-risk breast cancer-susceptibility alleles? Cancer Res. 2004;64(3):840-843. (Pubitemid 38176882)
43. Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005;97(11):813-822. (Pubitemid 40909124)
44. Vorechovsky I, Rasio D, Luo L, et al. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res. 1996;56(12):2726-2732. (Pubitemid 26175727)
45. Broeks A, Braaf LM, Huseinovic A, et al. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res. 2007;9(2):R26. (Pubitemid 350215161)
46. Su Y, Swift M. Outcomes of adjuvant radiation therapy for breast cancer in women with ataxia-telangiectasia mutations. JAMA. 2001;286(18):2233-2234. (Pubitemid 33063141)
47. Bernstein JL, Langholz B, Haile RW, et al. Study design: evaluating gene-environment interactions in the etiology of breast cancer-the WECARE study. Breast Cancer Res. 2004;6(3):R199-R214.
48. Bernstein JL, Teraoka S, Haile RW, et al. Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat. 2003;21(5):542-550. (Pubitemid 36529552)
49. Concannon P, Haile RW, Borresen-Dale AL, et al. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Res. 2008;68(16):6486-6491.
50. Langholz B, Borgan Ø. Counter-matching: a stratified nested case-control sampling method. Biometrika. 1995;82(1):69-79.
51. Langholz B, Thomas DC, Stovall M, et al. Statistical methods for analysis of radiation effects with tumor and dose location-specific information with application to the WECARE study of asynchronous contralateral breast cancer. Biometrics. 2009;65(2):599-608.
52. Huberman M, Langholz B. Application of the missing-indicator method in matched case-control studies with incomplete data. Am J Epidemiol. 1999;150(12):1340-1345.
53. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11(5):863-874. (Pubitemid 32447869)
54. Sunyaev S, Ramensky V, Koch I, Lathe W III, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet. 2001;10(6):591-597. (Pubitemid 32229363)
55. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38(8):873-875. (Pubitemid 44141653)
56. Le Marchand L, Wilkens LR. Design considerations for genomic association studies: importance of gene-environment interactions. Cancer Epidemiol Biomarkers Prev. 2008;17(2):263-267. (Pubitemid 351272773)
57. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Jr. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002;158(2):220-235. (Pubitemid 34851818)